- Home
- ROIV vs GLOB Comparison
ROIV vs GLOB Comparison
Compare ROIV & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- GLOB
- Stock Information
- Founded
- ROIV 2014
- GLOB 2003
- Country
- ROIV United Kingdom
- GLOB Luxembourg
- Employees
- ROIV N/A
- GLOB N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- GLOB EDP Services
- Sector
- ROIV Health Care
- GLOB Technology
- Exchange
- ROIV Nasdaq
- GLOB Nasdaq
- Market Cap
- ROIV 8.4B
- GLOB 9.9B
- IPO Year
- ROIV N/A
- GLOB 2014
- Fundamental
- Price
- ROIV $11.27
- GLOB $210.16
- Analyst Decision
- ROIV Strong Buy
- GLOB Buy
- Analyst Count
- ROIV 8
- GLOB 19
- Target Price
- ROIV $17.93
- GLOB $230.68
- AVG Volume (30 Days)
- ROIV 5.1M
- GLOB 350.5K
- Earning Date
- ROIV 02-11-2025
- GLOB 02-13-2025
- Dividend Yield
- ROIV N/A
- GLOB N/A
- EPS Growth
- ROIV N/A
- GLOB 7.25
- EPS
- ROIV 5.89
- GLOB 3.84
- Revenue
- ROIV $129,128,999.00
- GLOB $2,353,911,000.00
- Revenue This Year
- ROIV $15.98
- GLOB $17.70
- Revenue Next Year
- ROIV N/A
- GLOB $14.19
- P/E Ratio
- ROIV $1.91
- GLOB $55.61
- Revenue Growth
- ROIV 145.68
- GLOB 17.35
- 52 Week Low
- ROIV $9.69
- GLOB $151.68
- 52 Week High
- ROIV $13.06
- GLOB $251.50
- Technical
- Relative Strength Index (RSI)
- ROIV 46.46
- GLOB 43.03
- Support Level
- ROIV $10.89
- GLOB $202.47
- Resistance Level
- ROIV $11.26
- GLOB $221.42
- Average True Range (ATR)
- ROIV 0.36
- GLOB 6.62
- MACD
- ROIV -0.02
- GLOB -0.17
- Stochastic Oscillator
- ROIV 47.75
- GLOB 34.11
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.